Advancements in oncological research is behind the increased demand within the global chemotherapy induced peripheral neuropathy market. The growing incidence of leukaemia across the world has driven the medical research industry to take stern measures and decisions. Increased use of chemotherapy can also be explained in terms of the aforementioned healthcare deadlock. The growing use of chemotherapy has also triggered peripheral neuropathy amongst a larger group of cancer patients. The severe symptoms associated with the occurrence of chemotherapy induced peripheral neuropathy has driven the medical industry to invest in treatment of the condition. The high annual number of cases for neuropathy has further intensified the concerns of the medical industry. The aforementioned factors are actively contributing to the growth of the global chemotherapy induced peripheral neuropathy market.
In this review by Transparency Market Research (TMR), several vital drivers of demand within the chemotherapy induced peripheral neuropathy market have been enunciated. Government bodies are allocating a handsome share of their annual GDP to healthcare and medical research. Revenues from this budget shall trickle down to the global chemotherapy induced peripheral neuropathy market. The COVID-19 pandemic has also enabled the medical fraternity to pull in fresh revenues. Henceforth, the global chemotherapy induced peripheral neuropathy market endows key growth opportunities in recent times.
The evident symptoms of peripheral neuropathy make it easy to diagnose the condition. However, treatment and management of the condition requires constant monitoring of vitals and other medical parameters. The vendors operating in the chemotherapy induced peripheral neuropathy market are making ceaseless efforts to develop effective drugs and medications to manage the condition. The existence of cancerous cells in the body of patients makes it crucial to administer mild doses of drugs for managing peripheral neuropathy. Henceforth, the market players in the global chemotherapy induced peripheral neuropathy market are ramping up their investments in oncological research.
Harvard Health Reviews have been providing relevant cues for management and treatment of neuropathy. Several vendors in the chemotherapy induced peripheral neuropathy market are projected to collaborate with Harvard’s research fraternity in order to reap the benefits of collaborative research. Insights from the Harvard Medical School have already helped several companies and research units in understanding the nature and symptoms of chemotherapy induced peripheral neuropathy. Some of the leading vendors operating in the chemotherapy induced peripheral neuropathy market are Asahi Kasei Pharma, Nemus Bioscience, Metys Pharmaceuticals, MAKScientific, PledPharma, Sova Pharmaceuticals, and Immune Pharmaceuticals.
The domain of oncology holds primal value for the healthcare and medical industries. Development of a resilient line of treatment for various forms of cancer has been a formidable challenge for the medical and healthcare industry. Despite handsome investments in cancer research, medical researchers have only tasted partial success in terms of developing effective treatment lines. Therefore, new research lines are continually being roped in across the medical industry.
Chemotherapy is a painful, last resort available to the available to the medical researchers. Therefore, cancer patients in the final stages of cancer are subjected to multiple rounds of chemotherapy. This results in the occurrence of chemotherapy induced peripheral neuropathy, furthering the pain in patients. As this vicious circle in oncology intensifies, medical researchers are focusing on developing effective medications to manage and control peripheral neuropathy. Use of opioids and antidepressants for management of cancer induced peripheral neuropathy has gained momentum in recent years.